Announcement PDF Appendix 3Y Change of Director’s Interest Notice Rule 3.19A.2 Appendix 3Y Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/09/01 Amended 01/01/11 Name of entity LTR Pharma Limited (ASX:LTP) ABN 42 103 087 449 We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act. Name of Director Date of last notice Lee Rodne 13 December 2023 Part 1 - Change of director’s relevant interests in securities In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part. Direct or indirect interest Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. Date of change No. of securities held prior to change Class + See chapter 19 for defined terms. 01/01/2011 (1) (2) (3) (4) (1) (2) (3) (4) (1) (2) (3) (4) (1) Direct Indirect Indirect Indirect N/A LTR Medical Pty Ltd LTR Consulting Pty Ltd Trexapharm Inc 2 December 2024 N/A N/A N/A 1,129,641 Fully Paid Ordinary Shares 1,000,000 Unlisted Options exercisable at $0.22 per option expiring 31 October 2028 (2) 46,373,750 Fully Paid Ordinary Shares (3) 982,143 Fully Paid Ordinary Shares (4) 4,188,000 Fully Paid Ordinary Shares (1) Unlisted Options exercisable at $2.52 per option expiring 2 December 2028 (2) N/A (3) N/A (4) N/A Appendix 3Y Page 1 Appendix 3Y Change of Director’s Interest Notice Number acquired (1) (2) (3) (4) Number disposed N/A Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation 100,000 N/A N/A N/A No cash consideration No. of securities held after change (1) 1,129,641 Fully Paid Ordinary Shares 1,000,000 Unlisted Options exercisable at $0.22 per option expiring 31 October 2028 100,000 Unlisted Options exercisable at $2.52 per option expiring 2 December 2028 (2) 46,373,750 Fully Paid Ordinary Shares (3) 982,143 Fully Paid Ordinary Shares (4) 4,188,000 Fully Paid Ordinary Shares Nature of change Grant of 100,000 unlisted options in accordance with a resolution of shareholders at the 2024 Annual General Meeting on the terms and conditions described in the Notice of Annual General Meeting and the Explanatory Notes which accompanied the Notice. Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buyback Part 2 – Change of director’s interests in contracts Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part. Detail of contract Nature of interest N/A N/A Name of registered holder (if issued securities) N/A Date of change N/A No. and class of securities to which N/A interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed Interest acquired Interest disposed + See chapter 19 for defined terms. Appendix 3Y Page 2 N/A N/A 01/01/2011 Appendix 3Y Change of Director’s Interest Notice Value/Consideration N/A Interest after change N/A Note: If consideration is non-cash, provide details and an estimated valuation Part 3 – +Closed period Were the interests in the securities or contracts detailed N/A above traded during a +closed period where prior written clearance was required? If so, was prior written clearance provided to allow the N/A trade to proceed during this period? If prior written clearance was provided, on what date was N/A this provided? + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 3 Appendix 3Y Change of Director’s Interest Notice Rule 3.19A.2 Appendix 3Y Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/09/01 Amended 01/01/11 Name of entity LTR Pharma Limited (ASX:LTP) ABN 42 103 087 449 We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act. Name of Director Date of last notice Julian Chick 13 December 2023 Part 1 - Change of director’s relevant interests in securities In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part. Direct or indirect interest Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. Date of change No. of securities held prior to change Class Number acquired Number disposed Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation + See chapter 19 for defined terms. 01/01/2011 (1) (2) (1) (2) Direct Indirect N/A LTR Medical Pty Ltd (1) 2 December 2024 (2) N/A (1) 808,492 Fully Paid Ordinary Shares 500,000 Unlisted Options exercisable at $0.22 per option expiring 31 October 2028 (2) 46,373,750 Fully Paid Ordinary Shares (1) Unlisted Options exercisable at $2.52 per option expiring 2 December 2028 (2) N/A (1) 100,000 (2) N/A N/A No cash consideration Appendix 3Y Page 1 Appendix 3Y Change of Director’s Interest Notice No. of securities held after change Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buyback (1) 808,492 Fully Paid Ordinary Shares 500,000 Unlisted Options exercisable at $0.22 per option expiring 31 October 2028 100,000 Unlisted Options exercisable at $2.52 per option expiring 2 December 2028 (2) 46,373,750 Fully Paid Ordinary Shares Grant of 100,000 unlisted options in accordance with a resolution of shareholders at the 2024 Annual General Meeting on the terms and conditions described in the Notice of Annual General Meeting and the Explanatory Notes which accompanied the Notice. Part 2 – Change of director’s interests in contracts Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part. Detail of contract Nature of interest N/A N/A Name of registered holder (if issued securities) N/A Date of change N/A No. and class of securities to which N/A interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed Interest acquired Interest disposed Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation Interest after change N/A N/A N/A N/A Part 3 – +Closed period Were the interests in the securities or contracts detailed N/A above traded during a +closed period where prior written clearance was required? If so, was prior written clearance provided to allow the N/A trade to proceed during this period? + See chapter 19 for defined terms. Appendix 3Y Page 2 01/01/2011 Appendix 3Y Change of Director’s Interest Notice If prior written clearance was provided, on what date was N/A this provided? + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 3 Appendix 3Y Change of Director’s Interest Notice Rule 3.19A.2 Appendix 3Y Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/09/01 Amended 01/01/11 Name of entity LTR Pharma Limited (ASX:LTP) ABN 42 103 087 449 We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act. Name of Director Date of last notice Maja McGuire 13 December 2023 Part 1 - Change of director’s relevant interests in securities In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part. Direct or indirect interest Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. Date of change No. of securities held prior to change Class Number acquired Number disposed Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation + See chapter 19 for defined terms. 01/01/2011 (1) (2) (1) (2) Direct Indirect N/A Maja McGuire ATF Scaraf Trust (1) 2 December 2024 (2) N/A (1) N/A (2) 235,492 Fully Paid Ordinary Shares 500,000 Unlisted Options exercisable at $0.22 per option expiring 31 October 2028 (1) Unlisted Options exercisable at $2.52 per option expiring 2 December 2028 (2) N/A (1) 100,000 (2) N/A N/A No cash consideration Appendix 3Y Page 1 Appendix 3Y Change of Director’s Interest Notice No. of securities held after change Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buyback (1) 100,000 Unlisted Options exercisable at $2.52 per option expiring 2 December 2028 (2) 235,492 Fully Paid Ordinary Shares 500,000 Unlisted Options exercisable at $0.22 per option expiring 31 October 2028 Grant of 100,000 unlisted options in accordance with a resolution of shareholders at the 2024 Annual General Meeting on the terms and conditions described in the Notice of Annual General Meeting and the Explanatory Notes which accompanied the Notice. Part 2 – Change of director’s interests in contracts Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part. Detail of contract Nature of interest N/A N/A Name of registered holder (if issued securities) N/A Date of change N/A No. and class of securities to which N/A interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed Interest acquired Interest disposed Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation Interest after change N/A N/A N/A N/A Part 3 – +Closed period Were the interests in the securities or contracts detailed N/A above traded during a +closed period where prior written clearance was required? If so, was prior written clearance provided to allow the N/A trade to proceed during this period? + See chapter 19 for defined terms. Appendix 3Y Page 2 01/01/2011 Appendix 3Y Change of Director’s Interest Notice If prior written clearance was provided, on what date was N/A this provided? + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 3